UBS O'Connor’s Cellectis CLLS Stock Holding History

UBS O'Connor’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-40,000	Closed	-$1.38M	–	804
2015 Q1	$1.38M	Buy	+40,000	New	+$1.45M	0.01%	471

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.46% 1-Year Est. Return

UBS O'Connor's CLLS Position: Q2 2015 in Review

UBS O'Connor sold out of Cellectis (CLLS) in Q2 2015, closing a stake of 40,000 shares — an estimated $1.38M sold.

UBS O'Connor first reported a position in CLLS in Q1 2015 and held it in 1 quarter. The position peaked at $1.38M in Q1 2015. 40 funds tracked by Wall St. Rank hold CLLS as of Q2 2015.

UBS O'Connor reported no remaining Cellectis position as of Q2 2015 after selling out during the quarter.
UBS O'Connor sold 40,000 Cellectis shares in Q2 2015, an estimated $1.38M.
UBS O'Connor first reported a position in Cellectis in Q1 2015 and held it in 1 quarter.
UBS O'Connor's Cellectis position peaked at $1.38M in Q1 2015.
40 funds tracked by Wall St. Rank held Cellectis as of Q2 2015.

Based on UBS O'Connor's 13F filing for Q2 2015, filed 13 Aug 2015.